Cosentyx carries a retail price of roughly $10,700 to $11,100 per monthly dose, making it one of the more expensive biologic medications on the market. What you actually pay, though, depends heavily on your insurance type and whether you qualify for manufacturer assistance. Many commercially insured patients pay little to nothing out of pocket, while others face thousands of dollars a year.
Retail Price Without Insurance
If you’re paying cash at a pharmacy with no insurance or discount program, Cosentyx costs between about $10,280 and $11,050 per carton for the standard adult dose. The exact price depends on the delivery format: a single Sensoready pen (150 mg) runs around $10,695, while the newer UnoReady pen (300 mg in one injection) averages about $10,960. A lower-dose syringe used for certain pediatric patients costs roughly $5,383. These are average retail figures reported by GoodRx and can vary by pharmacy and location.
Because Cosentyx requires monthly injections after an initial loading phase, the annual retail cost for a maintenance patient lands in the range of $125,000 to $130,000 per year before any discounts or insurance.
Cost With Commercial Insurance
Most people with employer-sponsored or marketplace insurance pay far less than the sticker price. Data from the Colorado Prescription Drug Affordability Board found that the average annual out-of-pocket cost for commercially insured patients was $2,801, which works out to roughly $233 per month. In a typical month, that breaks down to about $74 toward your deductible, $92 in coinsurance, and $92 in copays.
The range is wide, though. About 57% of commercially insured patients paid between $0 and $50 total per month, likely because they had strong prescription coverage or were using a copay assistance card. On the other end, some patients paid as much as $12,100 to $12,150 in a year, typically those with high-deductible plans or significant coinsurance requirements for specialty drugs.
Your plan’s formulary matters. If Cosentyx is listed as a preferred biologic on your plan, your cost share will be lower. If it’s non-preferred or requires step therapy (trying a cheaper drug first), you may face higher out-of-pocket costs or need your doctor to submit a prior authorization before coverage kicks in.
Cost With Medicare
Under Medicare Part D, Cosentyx is classified as a Tier 5 specialty drug. This is the highest cost tier, reserved for expensive biologics and specialty medications. Tier 5 drugs typically carry coinsurance (a percentage of the drug’s cost) rather than a flat copay, which can mean substantial out-of-pocket spending, especially during the deductible and coverage gap phases of your plan.
All Cosentyx formulations on Medicare plans require prior authorization, and most have quantity limits. The Inflation Reduction Act capped total out-of-pocket Part D spending at $2,000 per year starting in 2025, which provides a meaningful ceiling for Medicare beneficiaries on expensive biologics like Cosentyx. Before that cap existed, annual costs could climb much higher.
Cost With Medicaid
Medicaid offers the lowest out-of-pocket costs for Cosentyx. Federal law caps Medicaid copays at $4 for preferred drugs and $8 for non-preferred drugs for most beneficiaries with income at or below 150% of the federal poverty level. Some states set copays even lower or waive them entirely. The bigger hurdle with Medicaid is usually getting the drug approved in the first place, since many state programs require prior authorization and may prefer other biologics before covering Cosentyx.
Novartis Copay Assistance Program
Novartis, the company that makes Cosentyx, offers a copay card that can reduce your cost to as little as $0 per dose. The program provides up to $16,000 per year toward the cost of the drug itself. If you receive Cosentyx as an infusion (for certain conditions), it also covers up to $150 per infusion session, to a maximum of $1,950 annually for administration costs.
This program is available to patients with commercial insurance. It does not apply if you have Medicare, Medicaid, or other government-funded coverage. Eligibility requirements can change, so check the Novartis website or ask your specialty pharmacy about current terms. For patients who qualify, the copay card is the single biggest factor in bringing costs down, which explains why the majority of commercially insured patients end up paying $50 or less per month.
How Dosing Affects Your Annual Cost
Cosentyx requires more frequent injections during the first month of treatment. The standard loading schedule for psoriasis is one injection per week for the first five weeks (at weeks 0, 1, 2, 3, and 4), followed by one injection per month starting at week 8. That means your first year of treatment includes about 13 doses rather than 12, and your out-of-pocket costs during those early months may be higher, especially if you haven’t yet met your deductible.
For conditions like ankylosing spondylitis, the loading phase may differ or be skipped entirely, which slightly changes the total annual cost. Your prescriber will determine the right schedule for your condition, but it’s worth factoring the loading phase into your budget for the first year.
Ways to Lower Your Cost
- Apply for the Novartis copay card if you have commercial insurance. This is the most effective way to reduce your spending and can bring your cost to $0.
- Check your plan’s formulary before filling. If a competing biologic is preferred on your plan and treats the same condition, switching could save money.
- Use a specialty pharmacy designated by your insurer. Many plans require this for biologics, and using an out-of-network pharmacy could mean paying full price.
- Ask about patient assistance programs if you’re uninsured or underinsured. Novartis and independent foundations sometimes offer free or reduced-cost medication for qualifying patients based on income.
- Time your refills around your deductible. If you’re close to meeting your annual deductible or out-of-pocket maximum, the timing of your first fill can affect how much you pay for the rest of the year.